If you are a medical professional, thank you for stopping by.
We know everyone is busy, and as such - it can be difficult to keep up-do-date with all the latest information available.
--- DID YOU KNOW ---
ICD-10 billing codes for Gadolinium have been approved.
The codes are important to everyone - patients, health insurance companies, the FDA, CDC, and other regulatory agencies.
All medical professionals are encouraged to learn more and use the available codes.
For more details, visit
https://www.aapc.com/codes/icd-10-codes/T56.82
The official government site for ICD-10 codes is the
https://www.cms.gov/medicare/coding-billing/icd-10-codes
We all know healthcare is complex.
No one expects a diagnostic tool intended to be helpful to introduce new, worsening, unexpected and unexplainable health concerns.
It is though due-diligence of reporting that we can begin to more accurately track and learn the impact retained gadolinium is having on human health.
It is very likely patients you see have had an MRI with contrast. As such, we encourage all offices to consider adding a question to your patient intake forms.
Have a open dialogue - be curious and look holistically at the patient needs.
Thank you for your help and dedication to your chosen profession and the patients you serve.
Cite and credit - ICD - ICD-10-CM - Coordination and Maintenance Committee. Source: cdc.gov.
https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm Meeting, March 8-9, 2022.
Diagnosis Agenda. Topic Packet. 2022-03-08-ICD-10-PCS-CM-Meeting-Materials |
CMS. Source: cdc.gov. https://www.cdc.gov/nchs/data/icd/march-2022-topic-packetfinal.1.pdf
Gadolinium Toxicity specifics located on pages 37-38.

MedWatch, the FDA’s medical product safety reporting program for health professionals, patients and consumers.
This site is used for reporting adverse events associated with Gadolinium-Based Contrast Agents
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
This site is used to report issues/con
MedWatch, the FDA’s medical product safety reporting program for health professionals, patients and consumers.
This site is used for reporting adverse events associated with Gadolinium-Based Contrast Agents
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
This site is used to report issues/concerns such as burns or device specifics
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm
The safety of magnetic resonance imaging contrast agents
https://pmc.ncbi.nlm.nih.gov/articles/PMC11345262/
"There is more than one side to the story concerning the safety of magnetic resonance imaging contrast agents.
Disinherited by the medical establishment, patients spend an eternal time in chronic symptomatic purgatory.
Escaping c
The safety of magnetic resonance imaging contrast agents
https://pmc.ncbi.nlm.nih.gov/articles/PMC11345262/
"There is more than one side to the story concerning the safety of magnetic resonance imaging contrast agents.
Disinherited by the medical establishment, patients spend an eternal time in chronic symptomatic purgatory.
Escaping complications from a gadolinium administration is not a sign of providence. It indicates that there are undiscovered factors. There are many knowledge gaps concerning magnetic resonance imaging contrast agents, the biology of gadolinium, and the mechanisms of complications."
The link to the FB clip where I discuss the importance of this article -
https://www.facebook.com/share/v/1AfdGqE83u/

For specific details related to Gadolinium-Based Contrast Agents - medication guides
are published by the brand name, and available from the FDA website.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm


Looking for a great place to start your research, reading, and learning?
Visit - https://pubmed.ncbi.nlm.nih.gov/
More than 44k papers exist.
Suggestion, as science and medicine are ever evolving, narrowing your search inclusive of the last 3-5 yrs may be helpful.


Some research is only available to readers through a subscription model. Reach out directly to those organizations for more details.
This paper, for example the paper referenced here is published by
Investigative Radiology
Semelka, Richard C. MD∗; Ramalho, Miguel MD†,‡. Gadolinium Deposition Disease: Current State of Knowledge and Expert
Some research is only available to readers through a subscription model. Reach out directly to those organizations for more details.
This paper, for example the paper referenced here is published by
Investigative Radiology
Semelka, Richard C. MD∗; Ramalho, Miguel MD†,‡. Gadolinium Deposition Disease: Current State of Knowledge and Expert Opinion. Investigative Radiology 58(8):p 523-529, August 2023. | DOI: 10.1097/RLI.0000000000000977
Copyright © 2024, 2025 Living with Gadolinium, LLC - All Rights Reserved.